This research estimates the benefits associated with percutaneous coronary interventions (PCIs) for patients with acute myocardial infarction (AMI) treated at hospitals in Pennsylvania. We studied 31 351 patients with AMI in Pennsylvania during the year 2000, including 10 170 who received PCI. Univariate comparisons between groups were made using χ2 tests for categorical outcomes and Student's t tests for continuous outcomes. A logit model for proportions was used to model the relationship between mortality and the proportion of AMI patients who received PCI. The mortality rate for patients undergoing PCI was significantly lower than for those being treated medically (1.4% vs 15.8%, P < .0001). Furthermore, significant survival benefits associated with PCI persisted when patients were stratified by age, sex, type of infarction, and severity at admission. At the hospital level, higher rates of PCI were associated with a significantly lower overall mortality rate among patients with AMI (P < .0001). (Am J Med Qual 2007;22:85-94)
American Heart Association.Heart Disease and Stroke Statistics-2003 Update. Dallas, TX: American Heart Association; 2002.
2.
GruppoItaliano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction . Lancet. 1986;1:397-402.
3.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
4.
Neuhaus KL, Feuerer W., Jeep-Tebbe S., Niederer W., Vogt A., Tebbe U.Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol.1989;14:1566-1569.
5.
TheInternational Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71-75.
6.
Weaver WD, Simes RJ, Betriu A., et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA.1997;278:2093-2098.
7.
Tilley S.Selection of reperfusion therapy for individual patients with evolving myocardial infarction. Eur Heart J.1997;18:1371-1381.
8.
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet1992 March 28; 339:753-770.
9.
International Joint Efficacy Comparison of Thrombolytics.Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995;346:329-336.
10.
TheContinuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med.1997;337: 1124-1130.
11.
Tebbe U., Michels R., Adgey J., et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. J Am Coll Cardiol.1998;31:487-493.
12.
Assessment of the Safety and Efficacy of a New Thrombolytic Investigators.Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999 ;354:716-722.
13.
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med.1997;337:1118-1123.
14.
Keeley EC, Boura JA, Grines CLPrimary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
15.
Widimsky P. , Budesinsky T., Vorac D., et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J.2003;24:94-104.
16.
Andersen HR , Nielsen TT, Rasmussen K., et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med.2003;349:733-742.
17.
O'Neill W., Timmis GC, Bourdillon PD, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med.1986;314:812-818.
18.
Grines CL, Browne KF, Marco J., et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med.1993;328:673-679.
19.
Zijlstra F. , de Boer MJ, Hoorntje JC, Reiffers S., Reiber JH, Suryapranata H.A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med.1993;328:680-684.
20.
Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJImmediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med.1993;328:685-691.
21.
The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators.A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction . N Engl J Med.1997; 336:1621-1628.
22.
Zijlstra F. , Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med.1999;341:1413-1419.
23.
Ribeiro EE, Silva LA, Carneiro R., et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol.1993; 22:376-380.
24.
Zijlstra F. , Beukema WP, van't Hof AW, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol.1997;29:908-912.
25.
Widimsky P. , Groch L., Zelizko M., Aschermann M., Bednar F., Suryapranata H.Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J.2000;21:823-831.
26.
de Boer MJ, Ottervanger JP, van't Hof AW, Hoorntje JC, Suryapranata H., Zijlstra F.Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol.2002;39:1723-1728.
27.
Ribichini F. , Steffenino G., Dellavalle A., et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study. J Am Coll Cardiol.1998; 32:1687-1694.
28.
Garcia E., Elizaga J., Perez-Castellano N., et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol.1999;33:605-611.
29.
Bonnefoy E., Lapostolle F., Leizorovicz A., et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002;360:825-829.
30.
Aversano T., Aversano LT, Passamani E., et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA.2002;287:1943-1951.
31.
Grines CL, Westerhausen DR, Jr., Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol.2002;39:1713-1719.
32.
Zijlstra F., Patel A., Jones M., et al. Clinical characteristics and outcome of patients with early (@#x3C;2 h), intermediate (2-4 h) and late (@#x3C;4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J.2002;23:550-557.
33.
Jacobs AKPrimary angioplasty for acute myocardial infarction—is it worth the wait?N Engl J Med.2003;349: 798-800.
34.
Schomig A., Kastrati A., Dirschinger J., et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med.2000;343:385-391.
35.
Le May MR, Labinaz M., Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol.2001;37(4):985-991.
36.
Vermeer F., Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart. 1999;82:426-431.
37.
Ellis SG, da Silva ER, Heyndrickx G., et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation. 1994;90:2280-2284.
38.
Califf RM, Topol EJ, Stack RS, et al. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction—phase 5 randomized trial. TAMI Study Group. Circulation. 1991;83:1543-1556.
39.
Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998;338:1785-1792.
40.
Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360: 743-751.
41.
Henderson RA , Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol.2003;42:1161-1170.
42.
Sirio CA, Sessa E., McGee JLPennsylvania Health Care Cost Containment Council—the role of a state health care agency in an evolving health care market. Am J Med Qual.1996;11:S82-S85.
43.
Localio AR, Hamory BH, Fisher AC, TenHave TRThe public release of hospital and physician mortality data in Pennsylvania . A case study. Med Care.1997;35:272-286. 44. Sirio CA, McGee JLPublic reporting of clinical outcomes— the data needs of health care stakeholders. Am J Med Qual.1996;11:S78-S81.
44.
Kimmel SE, Sauer WH, Brensinger C., Hirshfeld J., Haber HL, Localio ARRelationship between coronary angioplasty laboratory volume and outcomes after hospital discharge. Am Heart J.2002;143:833-840.
45.
Kimmel SE, Localio AR, Brensinger C., et al. Effects of coronary stents on cardiovascular outcomes in broad-based clinical practice. Arch Intern Med.2000;160:2593-2599.
46.
Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med.2003 ;163: 1430-1439.
47.
Kandzari DE , Hasselblad V., Tcheng JE, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J.2004;147:457-462.
48.
Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med.2002;346:957-966.
49.
Hannan EL, Racz MJ, Arani DT, Ryan TJ, Walford G., McCallister BDShort- and long-term mortality for patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol.2000;36:1194-1201.
50.
Saleem MA, Kannam H., Aronow WS, et al. The effects of off-normal hours, age, and gender for coronary angioplasty on hospital mortality in patients undergoing coronary angioplasty for acute myocardial infarction. Am J Cardiol.2004;93: 763-764.
51.
Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., Tolonen H., Ruokokoski E., Amouyel P.Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. 1999;353:1547-1557.
52.
Hasdai D., Behar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J.2002;23:1190-1201.
53.
Shihara M., Tsutsui H., Tsuchihashi M., Tada H., Kono S., Takeshita A.In-hospital and one-year outcomes for patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol.2002;90:932-936.
54.
Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
55.
Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med.1999;341:1949-1956.
56.
Nordmann AJ, Hengstler P., Harr T., Young J., Bucher HCClinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials . Am J Med.2004;116:253-262.
57.
Boersma E., Akkerhuis KM, Theroux P., Califf RM, Topol EJ, Simoons MLPlatelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation . 1999; 100:2045-2048.
58.
Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol.2000;36:2056-2063.
59.
French WJTrends in acute myocardial infarction management: use of the National Registry of Myocardial Infarction in quality improvement. Am J Cardiol.2000;85:5B-9B.
60.
Baldwin LM, MacLehose RF, Hart LG, Beaver SK, Every N., Chan L.Quality of care for acute myocardial infarction in rural and urban US hospitals . J Rural Health.2004;20:99-108.
61.
Soumerai SB , McLaughlin TJ, Ross-Degnan D., Christiansen CL, Gurwitz JHEffectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old . Arch Intern Med.2002;162:561-568.
62.
Gan SC, Beaver SK, Houck PM, MacLehose RF, Lawson HW, Chan L.Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med.2000;343:8-15.
63.
Marrugat J. , Sala J., Masia R., et al. Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempo de Espera. JAMA.1998;280:1405-1409.
64.
Lagerqvist B., Husted S., Kontny F., et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol.2002;40:1902-1914.
65.
de Winter RJ , Windhausen F., Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med.2005;353:1095-1104.
66.
Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. 1994;89:1545-1556.
67.
McCullough PA, O'Neill WW, Graham M., et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol.1998;32:596-605.
68.
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999;354:708-715.
69.
Spacek R., Widimsky P., Straka Z., et al. Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. Eur Heart J.2002;23:230-238.
70.
Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes . Ann Intern Med.2004;141:186-195.
71.
Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med.2001;344:1879-1887.
72.
Alpert JS, Thygesen K., Antman E., Bassand JPMyocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol.2000;36:959-969.
73.
Jollis JG, Romano PSPennsylvania's Focus on Heart Attack— grading the scorecard. N Engl J Med.1998;338:983-987.
74.
Stone GW, Grines CL, Browne KF, et al. Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. Am J Cardiol.1996;78:19-25.
